Skip to main content
. 2021 Jun 4;21(8):1–188.

Table 25:

Quality of Life Score After Cyanoacrylate Adhesive Closure vs. Radiofrequency Ablation

Author, Year (Study Design) Baseline Score, MN (SD)a Follow-Up Time Point Follow-Up Score, MN (SD)a P Value
CAC RFA CAC RFA
Disease-Specific Quality of Life: Aberdeen Varicose Vein Questionnaire
VeClose trial70–72,81
(RCT, noninferiority trial)
18.9 (9.0) 19.4 (9.9) 1 mo70 11.9 (7.1) 12.6 (8.3) 0.53b
3 mo70 11.6 (7.5) 10.7 (8.6)
6 mo72 10.2c(5.6c) 9.1c (7.1c) NS (NR)
12 mo72 9.7c (7.1c) 8.4c (6.5c) NS (NR)
24 mo72 8.2c (7.9c) 8.3c (7.5c) NS (NR)
36 mo72 7.3c (6.4c) 8.2c (7.8c) NS (NR)
60 mo81 8.3 (9.6d) 6.6 (5.7d) .3418
Ovali and Sevin, 201966 (prospective comparative cohort) 17.43 (6.38) 18.21 (6.93) 12 mo 4.93 (1.56) 5.13 (1.49) .752
Bademci et al, 201964
(prospective comparative cohort)
MD 17 (range 15–21) 17 (11–21) 1 mo 7 (6–9) 8 (5–13) .10
6 mo 5 (4–7) 6 (3–10) .84
12 mo 4 (3–6) 4 (1–9) .61
Generic Quality of Life: EQ-5D TTO
VeClose trial70,81 (RCT, noninferiority trial) 0.935 (.113) 0.918 (.116) 1 mo70 0.965 (.113) 0.961 (.106) .34b
3 mo70 .965 (.095) .965 (.083)
60 mo81 0.97 (.08) .94 (.11) NR

Abbreviations: CAC, cyanoacrylate adhesive closure; EQ-5D TTO, EuroQol 5-Dimension Time Trade Off; MD, median; MN, mean; mo, month(s); NR, not reported; NS, not significant; RCT, randomized controlled trial; RFA, radiofrequency ablation; SD, standard deviation.

a

Unless otherwise noted values are mean and standard deviation.

b

Repeated-measures ANOVA comparing baseline, 1 mo, and 3 mo.70

c

Values approximated and/or calculated from data presented in figures in Morrison et al, 201972 using WebPlotDigitizer software.43

d

Standard deviation calculated from data presented in Figure 3 of Morrison et al, 202081 using WebPlotDigitizer software.43